Latest Breaking News On - கல்லீரல் ஆரோக்கியம் - Page 3 : comparemela.com

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 News provided by Share this article Share this article SALT LAKE CITY, May 6, 2021 /PRNewswire/  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. First Quarter Recent Corporate Highlights Announced positive topline results from the Phase 2 LiFT ( Liver Fat intervention with oral Testosterone ) clinical study, investigating LPCN 1144 in biopsy-confirmed NASH male subjects Both LPCN 1144 treatment arms met the primary endpoint, change in hepatic fat fraction via magnetic resonance imaging proton density fat fraction ( MRI-PDFF ), with statistical significance

Lipocine incClarus therapeutics incLiver healthMetabolic regulationHigh fat diet inducedQuarter ended marchClarus therapeuticsPrivate securities litigation reform actConsolidated statementsMonths ended marchகிளாரஸ் சிகிச்சை இன்க்கல்லீரல் ஆரோக்கியம்வளர்சிதை மாற்ற ஒழுங்குமுறைகிளாரஸ் சிகிச்சைப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம்தொகுக்கப்பட்டு அறிக்கைகள்